Aarhus Universitetshospital, Skejby

Aarhus 8200

4 studies enrolling now · 11 studies all time

What they study most

Atherosclerotic Cardiovascular Disease (ASCVD), COVID, COVID-19, Carcinoma, Transitional Cell, Chronic Kidney Disease, Chronic Kidney Disease (CKD), Chronic Lymphocytic Leukemia, Crohn's Disease, Elevated Lp(a), Heart Failure, Neoplasm Metastasis, Obesity

Studies at this site

• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Recruiting now
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Recruiting now
• A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract — Recruiting now
• A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Recruiting now
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — Running, not enrolling
• A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes — Running, not enrolling
• An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension — Completed
• Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) — Completed
• Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy — Completed
• Safety and Clinical Performance of the Protecta ICD and CRT-D — Completed